Yungjin Pharm Co Ltd

Yungjin Pharm maintains a debt-to-equity ratio of 0.71, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is assessed as medium, with a current ratio of 1.52, suggesting it can cover short-term obligations but with limited buffer. Free cash flow stands at KRW 3.08 billion, while operating cash flow is KRW 10.55 billion, reflecting a healthy cash generation capacity despite capital expenditures of KRW 3.19 billion.

Profitability metrics show a return on equity (ROE) of 4.37% and a return on assets (ROA) of 1.75%, both below the typical thresholds for high-performing pharmaceutical firms. Gross profit of KRW 20.83 billion and operating income of KRW 4.32 billion indicate a relatively narrow margin structure, which may limit the company's ability to absorb cost increases or invest in R&D.

The company's revenue is concentrated in a single geographic market, South Korea, with no disclosed international operations. This lack of diversification increases exposure to domestic regulatory and economic shifts. No segment-specific revenue breakdown is available, but the absence of disclosed international operations suggests a high concentration risk.

Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or contraction projected in the next fiscal year. The current fiscal year revenue of KRW 64.95 billion reflects a steady performance, but the absence of disclosed growth initiatives or new product launches suggests limited upside potential.

Risk factors include a medium liquidity risk due to the current ratio and a negative net cash position after subtracting total debt. Dilution risk is assessed as low, with no near-term pressure from share issuance or convertible instruments. However, the company's reliance on debt financing and limited free cash flow could constrain its ability to fund expansion or R&D without external capital.

Recent filings and transcripts do not disclose any material events or strategic shifts. The company appears to be operating within a stable but low-growth environment, with no significant new product approvals or regulatory challenges reported in the latest available data.

Yungjin Pharmaceutical Co (003520.KS) has undergone a significant update to its risk and classification profile, with the most material changes being the formal assignment of its economic sector to Healthcare and its primary activity to Pharmaceuticals. These taxonomy classifications, previously unrecorded, are now established as medium-severity updates, providing a clearer structural definition of the company’s operational focus within the broader market. Alongside these sectoral definitions, the company’s risk assessment framework has been populated with specific metrics. Dilution risk is now classified as low, indicating a stable capital structure with minimal threat of share value erosion from new issuances. This assessment is supported by the company’s current financial data [doc:003520.ks-ha-financials]. Conversely, liquidity risk has been assigned a medium rating, suggesting that while the company maintains operational stability, there may be moderate constraints or variability in its short-term cash flow management. This medium-severity classification highlights an area of ongoing monitoring for investors, balancing the low dilution risk with the need for adequate liquid assets. The significance of these updates lies in the establishment of a baseline for future analysis. With no analyst coverage, index memberships, or top holder data currently tracked, these newly defined risk and taxonomy fields serve as the primary indicators for evaluating Yungjin Pharmaceutical’s financial health and sector positioning. The absence of prior values for these fields underscores the importance of these initial classifications in shaping future investment perspectives.

Return on equity of 4.37% surpasses the pharmaceutical cohort median of 2.92%, reflecting better capital utilization efficiency.

Cash conversion ratio of 2.58 ranks in the top quartile, significantly exceeding the cohort median of 0.95.

Free cash flow improved by 70.7% year-over-year, showing a strong recovery in cash generation capabilities.

Debt-to-equity ratio of 0.71 places the company in the bottom quartile, indicating significantly higher leverage than peers.

The company faces high credit risk, signaling potential difficulties in meeting financial obligations or securing favorable financing.

Medium liquidity risk flags potential challenges in meeting short-term financial obligations without significant asset liquidation.

Revenue KRW 218.38B, +11,4% YoY; Operating income −54,8% YoY.

• ▍Revenue KRW 218.38B, +11,4% YoY
• ▍Operating income −54,8% YoY
• ▍Net income −89,6% YoY
• ▍Free cash flow −76,3% YoY
• ▍Net margin -10.1%